“As
published in the scientific journal
Proceedings of the National Academy of Sciences, under the
direction of Dr. Greengard and spearheaded by Drs. Bill Netzer and Victor
Bustos, [Fisher Center scientists] further discovered that Gleevec and a
related compound mimic the effects of the protective mutations and thus can act
as models for the development of effective drugs to fight Alzheimer’s disease.
“The
cellular process responsible for the mutation’s protective effect was also
identified, which suggests that drugs targeting this process or pathway also
might provide protection against the development of Alzheimer’s disease.
“‘Four
approved drugs are currently used to treat Alzheimer’s cognitive symptoms and
these drugs produce modest, temporary benefits at best and do not prevent or delay
worsening of the disease,’ said Nobel Laureate Dr. Paul Greengard, Director of
The Fisher Center for Alzheimer’s Research. ‘This new finding opens the doors
for new treatments that may actually prevent Alzheimer’s disease from
developing, which would drastically decrease the number of people affected by
the disease.’
“In
a previous study conducted by the Fisher Center scientists, they discovered
that Gleevec lowers Aβ levels through indirect inhibition of γ-secretase
activity. In the current study, they report that Gleevec also achieves its
Aβ-lowering effects through an additional cellular mechanism. It renders APP
less susceptible to proteolysis by BACE without inhibiting BACE enzymatic
activity or the processing of other BACE substrates.
“‘This
study further confirms that treatment with drugs that indirectly modulate BACE
processing of APP but spare other BACE substrates while achieving therapeutic
concentrations in the brain might be effective in preventing or delaying the
onset of AD and could be safer than non-selective BACE inhibitor drugs,’ said
Dr. Victor Bustos, Senior Research Associate at the Fisher Center for Alzheimer’s
Research at The Rockefeller University.
“‘As
a direct result of the funding support we provide to the Fisher Center for
Alzheimer’s Research at The Rockefeller University, the lab has identified an
effective treatment model for preventing Alzheimer’s disease,’ said Kent L.
Karosen, President/CEO Fisher Center for Alzheimer’s Research Foundation. ‘Our
lab at The Rockefeller University is on the cutting edge of science and we are
pleased to fund their breakthrough research in our quest to find a cure for
Alzheimer’s.’”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.